Nutritional Intervention and Rehabilitation Treatment in Patients With Post-COVID Condition
NCT06063031 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146
Last updated 2024-11-15
Summary
SARS-CoV-2 is the coronavirus responsible for developing the disease known as COVID-19. Once the acute phase of the disease has passed, about 40% of the people who discharged continue to have symptoms, and of these, between 50 and 70% present them up to three months later. These persistent symptoms include physical aspects such as fatigue and dyspnea, but also cardiac such as palpitations, cognitive such as mental confusion, and psycho-emotional such as depression, anxiety, and stress. SARS-CoV-2 infection is associated with a hyperinflammatory state, including excessive inflammatory cell infiltration, inflammasomes activation. In this context, omega-3 metabolites (Special Pro-resolving Mediators-SPMs) restore the balance in nutritional and molecular levels of eicosanoids. A more direct and targeted way to increase SPMs levels is Omega3 Essential Nutrition with natural SPMs taken by mouth. Today, there are dietary supplements containing SPMs (LIPINOVA®), made from fish oil through a fractionation process. LIPINOVA® is a nutritional supplement patented by Solutex GC S.L., obtained through several fractionation stages (extraction, purification, separation, concentration) from rich-in-omega-3 fish oil (without additives). Each capsule contains 498 mg of fish oil and 2 mg of tocopherols. This represents a variable quantity from 50 to 150 mg of EPA (20%), a variable quantity from 100 to 225 mg of DHA (30%), as well as the following quantities of EPA and DHA active metabolites, obtained from a pool of natural lipid mediators contained in omega-3 oil: 40-200 mcg of 17-HDHA, 25-200 mcg of 18-HEPE and 20-100 mcg of 14-HDHA.
In addition to this, the appearance of this new health condition, post-COVID condition, has once again led physiotherapists to update themselves in search of the best evidence to guide the examination and necessary rehabilitation interventions in this type of patient. Studies have shown how physiotherapy sessions that include a multimodal program could be the most indicated for this type of patients. Patients with this condition present an increase in fatigue, dyspnea and a decrease in their functional capacity and, therefore, a decrease in their quality of life, due to various pathogenic mechanisms that include chronic hyperinflammation.
These patients could obtain greater health improvements in terms of their quality of life if a therapeutical exercise and education program based on tele-rehabilitation is implemented together with a natural nutritional supplement that generates a systemic anti-inflammatory effect through SPMs (omega- 3).
Conditions
- Post-COVID Condition
Interventions
- DIETARY_SUPPLEMENT
-
Active
Active nutritional supplement plus telerehabilitation
- OTHER
-
Placebo
Placebo nutritional supplement plus telerehabilitation
Sponsors & Collaborators
-
Solutex GC S.L.
collaborator INDUSTRY -
Instituto de Investigación Sanitaria Aragón
lead OTHER
Principal Investigators
-
Jorge Alamillo Salas, Dr · SALUD
-
Sandra Calvo Carrión., Dr · Universidad de Zaragoza
-
Beatriz Carpallo Porcar, MSc · Universidad San Jorge
-
Carolina Jiménez Sánchez, Dr · Universidad San Jorge
-
Ana Isabel Aller Blanco, Dr · SALUD
-
Elena Kolesnyk Sumskaya, Dr · SALUD
-
Esther del Corral Beamonte, Dr · SALUD
-
Pablo Herrero Gallego, Dr · Universidad de Zaragoza
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-26
- Primary Completion
- 2025-01-15
- Completion
- 2025-04-30
Countries
- Spain
Study Locations
More Related Trials
-
Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms
NCT04351763 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients
NCT00329485 ·Status: TERMINATED ·Phase: NA
-
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
NCT01055912 ·Status: COMPLETED ·Phase: PHASE2
-
Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC
NCT04631536 ·Status: UNKNOWN ·Phase: PHASE3
-
Therapeutic Drug Monitoring of Cardiac Medications
NCT03667781 ·Status: TERMINATED
-
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
NCT04615949 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Peritoneal Ultrafiltration in Cardio Renal Syndrome.
NCT03994874 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure
NCT01474486 ·Status: COMPLETED ·Phase: NA
-
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function
NCT00627653 ·Status: UNKNOWN ·Phase: NA
-
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
NCT05619653 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
NCT00655538 ·Status: COMPLETED ·Phase: PHASE2
-
Defibrotide in COVID-19 Pneumonia
NCT04335201 ·Status: COMPLETED ·Phase: PHASE2
-
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
NCT04795479 ·Status: COMPLETED ·Phase: PHASE1
-
Nicotinamide Riboside in Systolic Heart Failure
NCT03423342 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
NCT00353522 ·Status: COMPLETED ·Phase: PHASE2
-
Baroreflex Activation Therapy in Heart Failure
NCT01484288 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure
NCT01251406 ·Status: COMPLETED ·Phase: PHASE2
-
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
NCT04530604 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
NCT01439789 ·Status: TERMINATED ·Phase: PHASE3
-
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
NCT03455439 ·Status: COMPLETED
-
Oral Carnitine in Heart Failure Patients
NCT07201714 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
NCT04478071 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-Inflammatory Drug and Endothelial Function
NCT04161339 ·Status: UNKNOWN ·Phase: PHASE4
-
Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial
NCT04482621 ·Status: SUSPENDED ·Phase: PHASE2
-
A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
NCT06113692 ·Status: COMPLETED